During the last session, ADMA Biologics Inc. (NASDAQ:ADMA)’s traded shares were 2.75 million, with the beta value of the company hitting 0.97. At the end of the trading day, the stock’s price was $2.15, reflecting an intraday gain of 0.94% or $0.02. The 52-week high for the ADMA share is $2.32, that puts it down -7.91 from that peak though still a striking 53.02% gain since the share price plummeted to a 52-week low of $1.01. The company’s market capitalization is $389.54M, and the average trade volume was 2.79 million shares over the past three months.
ADMA Biologics Inc. (ADMA) received a consensus recommendation of a Buy from analysts. That translates to a mean rating of 1.50. ADMA has a Sell rating from 0 analyst(s) out of 2 analysts who have looked at this stock. 0 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 2 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -$0.08.
ADMA Biologics Inc. (NASDAQ:ADMA) trade information
ADMA Biologics Inc. (ADMA) registered a 0.94% upside in the last session and has traded in the green over the past 5 sessions. The stock spiked 0.94% in intraday trading to $2.15 this Wednesday, 06/22/22, hitting a weekly high. The stock’s 5-day price performance is 10.26%, and it has moved by 5.39% in 30 days. Based on these gigs, the overall price performance for the year is 30.30%.
ADMA Biologics Inc. (ADMA) estimates and forecasts
Yet analysts are ramping up their growth forecast for the fiscal year 2022. Revenue is predicted to grow 42.90% this quarter and then jump 46.20% in the quarter after that. In the rating firms’ projections, revenue will increase 58.80% compared to the previous financial year.
Revenue for the current quarter is expected to be $31 million as predicted by 2 analyst(s). Meanwhile, a consensus of 2 analyst(s) estimates revenue growth to $33.15 million by the end of Sep 2022.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings grew an estimated 20.40%. While earnings are projected to return 41.60% in 2022.
ADMA Biologics Inc. is due to release its next quarterly earnings between March 23 and March 28. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
ADMA Biologics Inc. (NASDAQ:ADMA)’s Major holders
ADMA Biologics Inc. insiders own 1.11% of total outstanding shares while institutional holders control 59.33%, with the float percentage being 59.99%. Perceptive Advisors Llc is the largest shareholder of the company, while 124 institutions own stock in it. As of Dec 30, 2021, the company held over 11.93 million shares (or 6.09% of all shares), a total value of $16.83 million in shares.
The next largest institutional holding, with 10.61 million shares, is of Nuveen Asset Management’s that is approximately 5.41% of outstanding shares. At the market price on Dec 30, 2021, these shares were valued at $14.96 million.
Also, the Mutual Funds coming in first place with the largest holdings of ADMA Biologics Inc. (ADMA) shares are Vanguard Total Stock Market Index Fund and Vanguard Extended Market Index Fund. Data provided on Dec 30, 2021 indicates that Vanguard Total Stock Market Index Fund owns about 5.23 million shares. This amounts to just over 2.67 percent of the company’s overall shares, with a $7.38 million market value. The same data shows that the other fund manager holds slightly less at 2.89 million, or about 1.47% of the stock, which is worth about $4.08 million.